News

The study compared GI-5005 plus standard of care (SOC) – pegylated interferon and ribavirin – versus SOC alone in patients with chronic genotype 1 hepatitis C virus (HCV)

Aveo Pharmaceuticals has reported data from its preclinical models which demonstrates that the company’s potent and selective triple VEGF receptor inhibitor, AV-951, exhibits robust inhibitory activity in its

The Plus Phase IIa clinical trial was conducted in 32 chronic hepatitis C patients in the US who had failed prior treatment. The Plus trial was designed to

The trial will evaluate the dose and duration of treatment of R7128 in combination with Roche’s Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) – in hepatitis C virus (HCV)

Intarcia’s Phase I study is evaluating the safety and pharmacokinetics of ITCA 650 at several doses over a treatment period of four weeks. ITCA 650 therapy is administered

Immunomedics has reported results that indicate CD74 is expressed at high levels in the majority of gastrointestinal tumors, which may allow milatuzumab, the company’s humanized anti-CD74 antibody, to

Antiviral activity was observed at all dose levels tested either as single agent or in combination with ribavirin. Treatment was well-tolerated with reversible, dose-dependent increases in liver enzyme

In this 15-day study, SCY-635 was well-tolerated with no serious adverse events, no discontinuations and no dose-limiting toxicities. At the highest dose tested in the study (900mg/day) SCY-635

Mr Mitchell is chairman of the board and CEO of Arrow Electronics, a provider of products, services and solutions to industrial and commercial users of electronic components and